GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results